In Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera
|
|
- Howard Hardy
- 5 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2007, p Vol. 51, No /07/$ doi: /aac Copyright 2007, American Society for Microbiology. All Rights Reserved. In Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera Nathan P. Wiederhold, 1,2 * Laura K. Najvar, 2 Rosie Bocanegra, 2 Destiny Molina, 2 Marcos Olivo, 2 and John R. Graybill 2 College of Pharmacy, The University of Texas at Austin, Austin, Texas, 1 and Department of Medicine/Infectious Diseases, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 2 Received 24 January 2007/Returned for modification 30 January 2007/Accepted 12 February 2007 In vitro studies have demonstrated that anidulafungin has greater potency than caspofungin against Candida glabrata. However, data from in vivo studies demonstrating that it has superior efficacy are lacking. The objective of this study was to compare the activities of anidulafungin and caspofungin against C. glabrata in a murine model of disseminated candidiasis. Two clinical C. glabrata isolates were used, including one with reduced caspofungin susceptibility. MICs were determined by broth microdilution in the presence and absence of sera. For the animal studies, mice were immunosuppressed with 5-fluorouracil one day prior to intravenous inoculation. Treatment with anidulafungin and caspofungin (0, 0.5, 1, 5, and 10 mg/kg of body weight per day) was begun 24 h later and was continued through day 7 postinoculation. The CFU were enumerated from kidney tissue. According to the standard microdilution methodology, anidulafungin had superior in vitro activity. However, this enhanced potency was attenuated by the addition of mouse and human sera. Caspofungin reduced the kidney fungal burden at lower doses compared to that achieved with anidulafungin in mice infected with the isolate with the lower MIC. Against the strain with the elevated caspofungin MIC, both anidulafungin and caspofungin were effective in reducing the kidney fungal burden at the higher doses studied. Despite the greater in vitro activity of anidulafungin in the absence of sera, both echinocandins were similarly effective in reducing the fungal burden in kidney tissue. The superior in vitro activity of anidulafungin did not confer enhanced in vivo efficacy against C. glabrata. Invasive candidiasis caused by Candida glabrata is of increasing clinical concern due to reports of the increasing frequency of cases and the high mortality rates in patients with multiple comorbidities, including elderly patients, immunocompromised patients with cancer, and patients in intensive care units (4, 15, 24, 34, 37). The various susceptibilities of C. glabrata isolates to fluconazole and the reduced response rates to other azole antifungals in breakthrough infections following fluconazole prophylaxis may limit the effectiveness of therapy for infections caused by this species (4, 7, 15, 27, 32, 33, 36). Furthermore, the use of amphotericin B formulations may be limited by infusion-related reactions and nephrotoxicity. Due to the inhibition of a fungal specific target, the beta- (1,3)-glucan synthase enzyme complex, the echinocandins (anidulafungin, caspofungin, and micafungin) avoid the overlapping toxicities and drug interactions with mammalian cells observed with the azoles and the polyenes (10, 35). Broth microdilution studies have demonstrated that each member of the echinocandin class has relatively good activity against Candida isolates, including C. glabrata and other non-c. albicans species (17, 35). Indeed, clinical studies have demonstrated the excellent efficacy of the echinocandins for the treatment of invasive candidiasis (19, 29, 31). * Corresponding author. Mailing address: UTHSCSA, PERC, MSC 6220, 7703 Floyd Curl Drive, San Antonio, TX Phone: (210) Fax: (210) wiederholdn@uthscsa.edu. Published ahead of print on 16 February In vitro studies comparing anidulafungin and caspofungin, including one our group at the University of Texas Health Science Center at San Antonio, have reported that anidulafungin has enhanced potency against C. glabrata (6, 8, 23). These studies, along with case reports describing clinical failures of caspofungin treatment in association with reduced in vitro activity, have raised the question of whether other members of this class would maintain their potencies at clinically relevant exposures in the presence of reduced caspofungin susceptibilities (11, 13, 26). However, few in vivo and clinical data from studies that have directly compared the efficacies of different echinocandins against isolates with elevated MICs exist. Therefore, the objective of this study was to compare the in vivo efficacies of anidulafungin and caspofungin against two C. glabrata clinical isolates, including one with reduced caspofungin susceptibility, in a murine model of invasive candidiasis. We hypothesized that anidulafungin would have superior in vivo efficacy, based on preliminary data demonstrating enhanced in vitro potency. MATERIALS AND METHODS Antifungals. Stock solutions were prepared by dissolving drug powders in dimethyl sulfoxide (anidulafungin; Vicuron Pharmaceuticals, King of Prussia, PA) or water (caspofungin; Merck & Co., Inc., Whitehouse Station, NJ). Stock solutions were diluted in RPMI medium buffered to ph 7.0 with M 4-morpholinepropanesulfonic acid or physiologic saline prior to each in vitro and in vivo experiment, respectively. Isolates. Two Candida glabrata clinical isolates (isolates and 05-62) were obtained from the Fungus Testing Laboratory at the University of Texas Health Science Center at San Antonio. The isolates were subcultured twice on Sabouraud dextrose agar before they were tested. Yeast cells were collected and 1616
2 VOL. 51, 2007 IN VIVO EFFICACY OF ANIDULAFUNGIN AND CASPOFUNGIN 1617 TABLE 1. MICs, IC 50 s, and IC 90 s for anidulafungin and caspofungin against C. glabrata isolates and by microdilution methodology in RPMI medium in the presence and absence of mouse and human sera Drug and serum present MIC 2 /MIC 0 ( g/ml) with or without mouse serum MIC 2 /MIC 0 ( g/ml) with or without human serum IC 50 /IC 90 ( g/ml R 2a ) with or without human serum Anidulafungin No serum 0.06/ / / / /0.16 (0.98) 0.31/0.41 (0.95) 5% serum 0.5/0.5 4/4 0.5/0.5 2/2 0.31/0.39 (0.99) 1.7/3.1 (0.97) 50% serum 1/1 8/8 1/2 8/16 Caspofungin No serum 1/2 2/ 32 1/2 2/ /1.6 (0.96) 1.2/ 32 (0.88) 5% serum 1/1 4/ /0.5 2/ /0.33 (0.99) 1.4/ 32 (0.95) 50% serum 2/2 8/ 32 1/1 4/ 32 a R 2 values are for the dose-response curves. washed in sterile saline three times, and the inocula were verified with a hemocytometer. The starting inocula were confirmed by plating serial dilutions and determining the colony counts. Susceptibility testing. Microdilution broth susceptibility testing was performed in duplicate according to the CLSI (formerly NCCLS) M27-A2 method in RPMI growth medium in the presence and absence of 5% and 50% (vol/vol) mouse and human sera (Sigma Aldrich, St. Louis, MO) (21). The MIC 2 was defined as the lowest concentration of anidulafungin or caspofungin that caused a significant decrease in turbidity ( 50%) compared to that of the growth control, and the MIC 0 was defined as the lowest concentration that resulted in no visual growth (an optically clear well) after 24 h of incubation. XTT reduction assay. The 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) colorimetric assay was performed in triplicate, according to previously reported methods (16), in the presence and absence of 5% (vol/vol) human sera. A standardized inoculum (100 l ofa to CFU/ml) was added to the wells of a 96-well microtiter plate containing serial twofold dilutions of antifungals in RPMI growth medium. The final anidulafungin and caspofungin concentrations ranged from to 32 g/ml. The trays were incubated at 37 C for 22 h, at which time 50 l of the tetrazolium salt XTT and the electron-coupling agent menadione were added to each well for final concentrations of 200 g/ml and 25 M, respectively. After 2 additional hours of incubation at 37 C, the absorbance at 492 nm was read with a microplate spectrophotometer (Syngergy HT; Biotek Instruments, Inc., Winooski, VT). The absorbance readings were converted to percent absorbance, with the absorbance of the growth control wells set at 100% and the absorbance of the medium control wells set at 0%. Animal model. Outbred ICR mice (Harlan Sprague-Dawley) weighing between 25 and 27 g were housed at five mice per cage and had access to food and water ad libitum. One day prior to inoculation the animals were immunosuppressed with intravenous 5-fluorouracil at 150 mg/kg of body weight. On day 0, the animals were infected intravenously with 0.2 ml of C. glabrata at approximately CFU/mouse. This study was approved by the Institutional Animal Care and Use Committee at the University of Texas Health Science Center at San Antonio, and all animals were maintained in accordance with the American Association for Accreditation of Laboratory Animal Care (20). Tissue burden studies. Antifungal therapy was begun 24 h after inoculation. Anidulafungin and caspofungin (0, 0.5, 1, 5, and 10 mg/kg per day) were administered by intraperitoneal injection until day 7 postinoculation. The mice were euthanized on day 8, and the kidney tissue was harvested and weighed. The kidneys were homogenized in sterile saline (total volume, 2 ml) with a tissue homogenizer (Polytron dispensing and mixing technology PT 2100; Kinematica, Cincinnati, OH). Serial dilutions were prepared in sterile saline and were plated in duplicate onto Sabouraud dextrose agar. Following 24 h of incubation at 37 C, the colonies were counted and the numbers of CFU per gram of kidney tissue for each animal were calculated. Each study consisted of between 10 and 15 animals per dosing group, and studies were conducted on two separate occasions to ensure reproducibility. Data analysis. Data from the XTT reduction assay were fit to a four-parameter inhibitory sigmoid model (modified Hill equation) by using computer curvefitting software (Prism 4; GraphPad Software, Inc., San Diego, CA) to derive 50% inhibitory concentrations (IC 50 s) and IC 90 s, as well as the steepness of the inhibitory dose-response curve (Hill slope). The goodness of fit for each isolate and drug combination was assessed by determination of the R 2 value and the standard error of the IC 50 value. Differences in fungal burden endpoints (CFU/g) were assessed for significance by using the Kruskal-Wallis test with Dunn s posttest for multiple comparisons. A P value of 0.05 was considered statistically significant for all comparisons. RESULTS Susceptibility testing. The results of susceptibility testing demonstrated that the addition of sera affected the potencies of anidulafungin and caspofungin differently. As shown in Table 1, in the absence of sera, anidulafungin had greater in vitro potency against both C. glabrata isolates by the standard broth microdilution methodology, with MIC 2 values 8 to 16 times lower than those of caspofungin. However, with the addition of either 5% mouse or 5% human serum, the MIC of anidulafungin increased by eightfold against each isolate. This reduction in potency was even greater in the presence of 50% serum (16- to 32-fold increases in the MIC 2 s). In contrast, the in vitro activity of caspofungin was relatively unchanged by the addition of sera to the growth medium. In fact, against isolate , the potency of caspofungin was somewhat enhanced in the presence of 5% human serum, as evident by reductions in the MIC 2 and MIC 0 values from 1 and 2 g/ml, respectively, to 0.25 g/ml. The changes in the MICs observed with the addition of sera are also supported by the XTT viability data (Table 1 and Fig. 1). As shown in Fig. 1A and C, in the absence of sera anidulafungin was more potent than caspofungin against both isolates, with lower IC 50 and IC 90 values. However, the addition of 5% human serum to the growth medium caused the dose-response curves for anidulafungin to shift to the right so that the curves for anidulafungin and caspofungin against each isolate were superimposed (Fig. 1B and D). XTT assays were also performed in the presence of 50% sera. However, this resulted in an inhibition in the reduction of the tetrazolium salt to the formazan derivatives not observed with the addition of 5% sera (data not shown). In vivo tissue burden. Despite the reduced in vitro potency of caspofungin compared to that of anidulafungin in the absence of sera, caspofungin maintained its in vivo potency against both C. glabrata isolates. Against isolate , caspofungin significantly reduced the tissue fungal burden at each dose tested, with the exception of the 5-mg/kg dose
3 1618 WIEDERHOLD ET AL. ANTIMICROB. AGENTS CHEMOTHER. FIG. 1. Sigmoidal dose-response curves for anidulafungin (F) and caspofungin (E) against C. glabrata isolates (A and B) and (C and D) in the absence of sera (A and C) and with the addition of 5% human sera (B and D). Symbols represent the means plus or minus standard deviations of experiments performed in triplicate for each drug. Curves were generated by fitting XTT viability data to a four-parameter inhibitory sigmoid model (modified Hill equation). (Fig. 2A), while anidulafungin resulted in no reductions in fungal burden compared to that for the control at doses below 5 mg/kg. However, the differences between anidulafungin and caspofungin at the higher doses studied (5 and 10 mg/kg) were not significant. Both agents were equally effective at reducing the burden of fungal isolate in kidney tissue (Fig. 2B), despite the reduced susceptibility to caspofungin in vitro by standard microdilution methods. DISCUSSION The echinocandins have been shown to be effective for the treatment of invasive candidiasis in clinical trials. In a randomized, double-blind study, a favorable response at the end of the study was noted in 73.4% of patients who received caspofungin but only 61.7% of those randomized to receive amphotericin B deoxycholate (P 0.09) (19). Micafungin has also been shown to have efficacy similar to that of liposomal amphotericin B for the treatment of invasive candidiasis (31), while anidulafungin proved to be superior to fluconazole at the end of therapy and at 2 weeks after the end of therapy (29). More recently, in a headto-head comparison, micafungin and caspofungin were shown to be equally effective in patients with candidemia or invasive candidiasis (3). Whether one member of this class has superior efficacy against infections caused by a particular Candida species remains unknown. Clinical trials to date have not been powered to show such differences; therefore, the response rates according to pathogen have been similar between treatment groups. Our hypothesis that anidulafungin has superior in vivo ac- FIG. 2. Fungal burden as measured by the numbers of CFU per gram of kidney tissue in mice that received the control preparation ( ), anidulafungin (F), or caspofungin (E) at doses of 0.5, 1, 5, and 10 mg/kg as treatment against Candida glabrata infection. (A) Candida glabrata isolate ; (B) Candida glabrata isolate Each group consisted of 24 mice. The line for each group represents the median fungal burden., P 0.05 versus the results for the control.
4 VOL. 51, 2007 IN VIVO EFFICACY OF ANIDULAFUNGIN AND CASPOFUNGIN 1619 tivity was based on the enhanced in vitro potency of this echinocandin against C. glabrata reported in the literature (1, 8, 22, 23, 30). Against C. glabrata, MICs from multicenter surveillance studies for members of this class have ranged from to 2 g/ml, with anidulafungin having increased potency (8, 23). One study of 2,000 bloodstream Candida isolates from two multicenter clinical trials, including 458 C. glabrata isolates, reported lower MIC 50 and MIC 90 values for anidulafugin compared to those for caspofungin for each Candida species, with the exception of C. parapsilosis (23). Similarly, previous work from our group demonstrated that anidulafungin had greater in vitro potency against C. glabrata, as evident by the lower MIC, IC 50, and IC 90 values and as supported by the results of time-kill studies (6). Despite the enhanced in vitro potency of anidulafungin, treatment with anidulafungin did not result in greater reductions in tissue burdens compared to those achieved by treatment with caspofungin. However, the lack of superior in vivo potency of anidulafungin was not due to the inability of this agent to lower colony counts but, rather, was due to the ability of caspofungin to maintain in vivo activity, despite its reduced in vitro potency. In fact, against the more sensitive isolate, caspofungin was more effective than anidulafungin in reducing the tissue burden at the lower doses studied, while both agents were equally effective against the isolate with elevated caspofungin MIC 0 values. The ability of caspofungin to maintain in vivo efficacy, despite its reduced in vitro potency, is not wholly unexpected. Our data are consistent with evidence that suggests that isolates with echinocandin MIC 2 values of 2 g/ml should be regarded as susceptible (28). In a review of the caspofungin clinical trial database, Kartsonis et al. reported that infections caused by Candida isolates with caspofungin MICs of 1 to 2 g/ml responded as well as those with lower MICs (0.25 and 0.5 g/ml) (12). However, it is unclear from this study if infections caused by isolates with higher caspofungin MICs would also respond, since only three isolates with MICs of 4 g/ml were included. The effects of sera on the activities of echinocandins are not fully understood. In the current study the in vivo efficacies of both echinocandins were consistent with the in vitro activities observed with the addition of sera to the growth medium. Previous studies have reported both positive and negative effects of sera on the activities of members of this class. Using the XTT viability assay, Chiller et al. demonstrated that caspofungin has enhanced inhibitory activity against A. fumigatus in the presence of serum concentrations ranging from 0.05 to 5% (5). Prior heating of the sera did not negate this enhanced activity. Interestingly, in contrast, recent studies have reported a decrease in the activity of echinocandin in the presence of higher concentrations of human sera. Mochizuki et al. reported that the MIC of micafungin against C. albicans increased eightfold in the presence of inactivated serum (18). However, the activity of micafungin remained greater than 50-fold higher than the free concentrations predicted by the protein binding ratio. A recent study comparing each of the three available echinocandins reported a tempering of the activity of each agent with the addition of 50% human sera, resulting in the neutralization of the enhanced potency of micafungin relative to that of caspofungin both in vitro and in vivo (25). In the current study, the addition of 5% and 50% sera negatively modulated the activity of anidulafungin, while the activity of caspofungin was either unchanged or slightly enhanced. Similar to the report by Park et al. (25), our in vitro data were consistent with the results from the animal studies. An alternative explanation for the differences in the in vivo activities of these agents compared to those observed in vitro in the absence of sera could be differences in the pharmacokinetic parameters. While differences in some pharmacokinetic parameters (e.g., transfer rate constants between the kidney tissue, other tissue sites, and the central compartment) for anidulafungin and caspofungin have been observed in mice, both agents persist in the kidneys at concentrations above their respective MIC 90 values for C. glabrata for an extended period following administration of a single dose (9, 14, 17). Furthermore, in this study and in clinical practice, both anidulafungin and caspofungin are administered on a daily basis. Thus, with repeated administration and persistence within the kidney tissue, the overall exposure to both agents is extensive. Prolonged tissue exposure is also observed clinically, as both anidulafungin and caspofungin have long elimination half-lives at steady state (range, 40 to 50 h) that are heavily influenced by tissue disposition and accumulation (Cancidas package insert [Merck & Co., Inc.] and Eraxis package insert [Pfizer, Inc., New York, NY]). While these data suggest that differences in pharmacokinetic parameters between anidulafungin and caspofungin are unlikely to explain the differences in the in vivo activities observed in the current study, the possibility that such differences exist cannot be ruled out. Another limitation of our study is the relative avirulence of C. glabrata in this animal model (2). Whether colony counts within kidney tissue alone are sufficient to gauge in vivo drug activity or whether differences in survival with the use of a more virulent species would also be observed between these agents is unknown. In conclusion, both anidulafungin and caspofungin were effective in reducing the tissue burden of C. glabrata isolates. However, discrepancies between the in vitro activities of each agent and their abilities to reduce the colony counts in vivo were observed. Consistent with the data from the animal studies, the addition of sera negated the enhanced in vitro potency of anidulafungin observed with standard broth microdilution methods and resulted in similar in vitro activities for the two echinocandins. ACKNOWLEDGMENTS This study was sponsored in part by a grant from Vicuron to J.R.G. J.R.G. has received research support from Pfizer, Inc., Schering-Plough Corporation, Merck & Co., and Fujisawa and has served as a consultant and speaker for Merck & Co. and Schering-Plough Corporation. N.P.W. has received research support from and served as a consultant and speaker for Pfizer, Inc. REFERENCES 1. Arevalo, M. P., A. J. Carrillo-Munoz, J. Salgado, D. Cardenes, S. Brio, G. Quindos, and A. Espinel-Ingroff Antifungal activity of the echinocandin anidulafungin (VER002, LY ) against yeast pathogens: a comparative study with M27-A microdilution method. J. Antimicrob. Chemother. 51: Atkinson, B. A., C. Bouthet, R. Bocanegra, A. Correa, M. F. Luther, and J. R. Graybill Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection with Candida glabrata in immunocompromised mice. J. Antimicrob. Chemother. 35: Betts, R. F., C. Rotstein, D. Talwar, M. Nucci, J. Dewaele, L. Arnold, L. Kovanda, C. Wu, and D. Buell Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-1308.
5 1620 WIEDERHOLD ET AL. ANTIMICROB. AGENTS CHEMOTHER. 4. Bodey, G. P., M. Mardani, H. A. Hanna, M. Boktour, J. Abbas, E. Girgawy, R. Y. Hachem, D. P. Kontoyiannis, and I. I. Raad The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am. J. Med. 112: Chiller, T., K. Farrokhshad, E. Brummer, and D. A. Stevens Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. Antimicrob. Agents Chemother. 44: Cota, J., M. Carden, J. R. Graybill, L. K. Najvar, D. S. Burgess, and N. P. Wiederhold In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob. Agents Chemother. 50: Diekema, D. J., S. Messer, L. Boyken, S. Tendolkar, J. Kroeger, R. Hollis, and M. A. Pfaller Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M Espinel-Ingroff, A Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36: Gumbo, T., G. L. Drusano, W. Liu, L. Ma, M. R. Deziel, M. F. Drusano, and A. Louie Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob. Agents Chemother. 50: Hector, R. F Compounds active against cell walls of medically important fungi. Clin. Microbiol. Rev. 6: Hernandez, S., J. L. Lopez-Ribot, L. K. Najvar, D. I. McCarthy, R. Bocanegra, and J. R. Graybill Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. 48: Kartsonis, N., J. Killar, L. Mixson, C. M. Hoe, C. Sable, K. Bartizal, and M. Motyl Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob. Agents Chemother. 49: Krogh-Madsen, M., M. C. Arendrup, L. Heslet, and J. D. Knudsen Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42: Louie, A., M. Deziel, W. Liu, M. F. Drusano, T. Gumbo, and G. L. Drusano Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother. 49: Malani, A., J. Hmoud, L. Chiu, P. L. Carver, A. Bielaczyc, and C. A. Kauffman Candida glabrata fungemia: experience in a tertiary care center. Clin. Infect. Dis. 41: Meletiadis, J., J. W. Mouton, J. F. Meis, B. A. Bouman, P. J. Donnelly, and P. E. Verweij Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2h-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39: Messer, S. A., J. T. Kirby, H. S. Sader, T. R. Fritsche, and R. N. Jones Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J. Antimicrob. Chemother. 54: Mochizuki, N., M. Aibiki, and Y. Matsumoto Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347: National Research Council Guide for the care and use of laboratory animals. National Academy Press, Washington, DC. 21. NCCLS Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA. 22. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Laverdiere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez- Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42: Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47: Pappas, P. G., J. H. Rex, J. Lee, R. J. Hamill, R. A. Larsen, W. Powderly, C. A. Kauffman, N. Hyslop, J. E. Mangino, S. Chapman, H. W. Horowitz, J. E. Edwards, and W. E. Dismukes A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37: Park, S., P. Paderu, and D. S. Perlin Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M Pelletier, R., I. Alarie, R. Lagace, and T. J. Walsh Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med. Mycol. 43: Perfect, J. R., K. A. Marr, T. J. Walsh, R. N. Greenberg, B. DuPont, J. de la Torre-Cisneros, G. Just-Nubling, H. T. Schlamm, I. Lutsar, A. Espinel- Ingroff, and E. Johnson Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36: Pfaller, M. A., and D. J. Diekema Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20: Reboli, A., C. Rotstein, P. Pappas, J. Schranz, D. Krause, and T. Walsh Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M Roling, E. E., M. E. Klepser, A. Wasson, R. E. Lewis, E. J. Ernst, and M. A. Pfaller Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY ) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagn. Microbiol. Infect. Dis. 43: Ruhnke, M., E. Kuse, P. Chetchotisakd, C. Arns da Cunha, and H. Diekmann-Berndt Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M Sterling, T. R., R. A. Gasser, Jr., and A. Ziegler Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host. Clin. Infect. Dis. 23: vanden Bossche, H., P. Marichal, F. C. Odds, L. Le Jeune, and M. C. Coene Characterization of an azole-resistant Candida glabrata isolate. Antimicrob. Agents Chemother. 36: Viscoli, C., C. Girmenia, A. Marinus, L. Collette, P. Martino, B. Vandercam, C. Doyen, B. Lebeau, D. Spence, V. Krcmery, B. De Pauw, and F. Meunier Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis. 28: Wiederhold, N. P., and R. E. Lewis The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin. Investig. Drugs 12: Wingard, J. R., W. G. Merz, M. G. Rinaldi, C. B. Miller, J. E. Karp, and R. Saral Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37: Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:
Received 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1942 1946 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.02434-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Activity
More informationEvaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility
Journal of Antimicrobial Chemotherapy (2008) 62, 1094 1100 doi:10.1093/jac/dkn304 Advance Access publication 25 July 2008 Evaluation of aminocandin and caspofungin against Candida glabrata including isolates
More informationIsolates from a Phase 3 Clinical Trial. of Medicine and College of Public Health, Iowa City, Iowa 52242, Wayne, Pennsylvania ,
JCM Accepts, published online ahead of print on 26 May 2010 J. Clin. Microbiol. doi:10.1128/jcm.00806-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationCaspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2011, p. 3254 3260 Vol. 55, No. 7 0066-4804/11/$12.00 doi:10.1128/aac.01750-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Caspofungin
More informationReceived 13 September 2006/Returned for modification 6 November 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 858 864 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01900-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Correlation
More informationComparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species
NEW MICROBIOLOGICA, 31, 257-262, 2008 Comparison of microdilution method and E-test procedure in susceptibility testing of caspofungin against Candida non-albicans species Anna Serefko, Renata Los, Anna
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationReceived 31 March 2009/Returned for modification 26 May 2009/Accepted 22 June 2009
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2009, p. 2766 2771 Vol. 47, No. 9 0095-1137/09/$08.00 0 doi:10.1128/jcm.00654-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Comparison
More informationSensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure
Basic research Sensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure Anna Serefko, Anna Malm Department of Pharmaceutical Microbiology, Medical
More informationMETHODS: MINIMAL INHIBITORY AND FUNGICIDAL CONCENTRATION AND TIME-KILLING STUDIES. Gobernado b. Fe, Valencia 46009, Spain.
AAC Accepts, published online ahead of print on 20 April 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.00160-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationReceived 25 March 2008/Returned for modification 12 May 2008/Accepted 15 June 2008
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2008, p. 2620 2629 Vol. 46, No. 8 0095-1137/08/$08.00 0 doi:10.1128/jcm.00566-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Correlation
More informationReceived 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1765 1771 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.02517-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter
More informationReceived 21 July 2008/Accepted 3 September 2008
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2008, p. 3585 3590 Vol. 46, No. 11 0095-1137/08/$08.00 0 doi:10.1128/jcm.01391-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Validation
More informationACCEPTED JCM REVISED. In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and
JCM Accepts, published online ahead of print on 1 November 00 J. Clin. Microbiol. doi:./jcm.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationReceived 26 July 2006/Returned for modification 10 October 2006/Accepted 16 October 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2007, p. 70 75 Vol. 45, No. 1 0095-1137/07/$08.00 0 doi:10.1128/jcm.01551-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Use of Fluconazole
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationon November 3, 2018 by guest
JOURNAL OF CLINICAL MICROBIOLOGY, June 2007, p. 1811 1820 Vol. 45, No. 6 0095-1137/07/$08.00 0 doi:10.1128/jcm.00134-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Multicenter
More informationIn Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2008, p. 150 156 Vol. 46, No. 1 0095-1137/08/$08.00 0 doi:10.1128/jcm.01901-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. In Vitro Susceptibility
More informationEfficacy of caspofungin and posaconazole in a murine model of disseminated Exophiala infection
Medical Mycology December 2007, 45, 685689 Original Articles Efficacy of caspofungin and posaconazole in a murine model of disseminated Exophiala infection ROBERT G. RIVARD, SUZANNE MCCALL, MATTHEW E.
More informationAntifungal Susceptibility Testing
Infect Dis Clin N Am 20 (2006) 699 709 Antifungal Susceptibility Testing Annette W. Fothergill, MA, MBA, MT(ASCP), CLS(NCA) a, Michael G. Rinaldi, PhD a,b, Deanna A. Sutton, PhD, MT, SM(ASCP), SM, RM(NRM)
More informationMultilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2011, p. 1543 1548 Vol. 55, No. 4 0066-4804/11/$12.00 doi:10.1128/aac.01510-09 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multilaboratory
More informationTable 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 2008-2011 Part 1: The Yeasts In this article, an update of recent changes to the CLSI antifungal standards for susceptibility testing of yeasts is presented. We
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationEchinocandin Susceptibility Testing of Candida Isolates Collected during a 1-Year Period in Sweden
JOURNAL OF CLINICAL MICROBIOLOGY, July 2011, p. 2516 2521 Vol. 49, No. 7 0095-1137/11/$12.00 doi:10.1128/jcm.00201-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Echinocandin
More informationThe incidence of invasive fungal infections
AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * Michael A. Pfaller, MD ABSTRACT *Based on a presentation given by Dr Pfaller at a symposium held in conjunction with the 43rd Interscience Conference
More informationInterlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2004, p. 3475 3482 Vol. 42, No. 8 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.8.3475 3482.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More information1* 1. Vijaya S. Rajmane, Shivaji T. Mohite
ISSN 2231-4261 ORIGINAL ARTICLE Comparison of the VITEK 2 Yeast Antifungal Susceptibility ing with CLSI Broth Microdilution Reference for ing Four Antifungal Drugs against Candida species Isolated from
More informationEfficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei
Journal of Antimicrobial Chemotherapy (2009) 63, 161 166 doi:10.1093/jac/dkn431 Advance Access publication 13 November 2008 Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic
More informationAAC Accepts, published online ahead of print on 21 March 2011 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 1 March 0 Antimicrob. Agents Chemother. doi:./aac.010- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationAntifungal susceptibility testing using the E test: comparison with the broth macrodilution technique
Journal of Antimicrobial Chemotherapy (996) 7, 65-7 Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique Sharon C. A. Chen, Maryann L. O'Donnell, Suzannah
More informationReceived 22 November 2007/Returned for modification 29 December 2007/Accepted 12 January 2008
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2008, p. 1396 1400 Vol. 52, No. 4 0066-4804/08/$08.00 0 doi:10.1128/aac.01512-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. In Vitro
More informationReceived 24 September 2001/Returned for modification 2 February 2002/Accepted 31 May 2002
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Sept. 2002, p. 2982 2989 Vol. 46, No. 9 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.9.2982 2989.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationIn Vitro Interactions of Antifungal agents and Tacrolimus against Aspergillus Biofilms
AAC Accepted Manuscript Posted Online 24 August 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.01510-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 In Vitro Interactions
More informationTreatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2005, p. 4895 4902 Vol. 49, No. 12 0066-4804/05/$08.00 0 doi:10.1128/aac.49.12.4895 4902.2005 Treatment of Candida glabrata Infection in Immunosuppressed Mice
More informationDivision of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI, USA
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00996.x In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus L. T. Ganesan, E. K.
More informationACCEPTED DIFFERENTIAL FUNGICIDAL ACTIVITY OF AMPHOTERICIN B AND VORICONAZOLE AGAINST ASPERGILLUS SPECIES DETERMINED BY MICROBROTH METHODOLOGY
AAC Accepts, published online ahead of print on 18 June 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.00345-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationAnidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies
Received: 1 February 2017 Revised: 11 May 2017 Accepted: 11 May 2017 DOI: 10.1111/myc.12641 ORIGINAL ARTICLE Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled
More informationReceived 15 October 2001/Returned for modification 27 May 2002/Accepted 24 June 2002
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2002, p. 3268 3272 Vol. 46, No. 10 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.10.3268 3272.2002 Copyright 2002, American Society for Microbiology. All Rights
More informationReceived 7 March 2002/Returned for modification 16 April 2002/Accepted 13 June 2002
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2002, p. 3204 3208 Vol. 40, No. 9 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.9.3204 3208.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationReceived 25 September 2006/Returned for modification 4 December 2006/Accepted 26 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 796 802 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01986-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Multicenter
More informationAntifungal susceptibility testing: Which method and when?
Antifungal susceptibility testing: Which method and when? Maiken Cavling Arendrup mad@ssi.dk SSI & Juan Luis Rodriguez Tudela jlrtudela@isciii.es ISCIII Agenda Summary of current standards and selected
More informationAmphotericin B, antifungal susceptibility, bloodstream infections, Candida spp., posaconazole, sus-
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01310.x Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital A. Bedini 1, C. Venturelli 2, C. Mussini 1, G.
More informationActivity of Posaconazole Combined with Amphotericin B against Aspergillus flavus Infection in Mice: Comparative Studies in Two Laboratories
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2004, p. 758 764 Vol. 48, No. 3 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.3.758 764.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationSYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II
SYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II DURAN NIZAMI 1, MUZ MUSTAFA 2, DURAN GULAY GULBOL 3, OZER BURCIN 1, ONLEN YUSUF 4 1 Mustafa
More informationon December 9, 2018 by guest
JCM Accepts, published online ahead of print on 27 June 2012 J. Clin. Microbiol. doi:10.1128/jcm.00937-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Progress in Antifungal
More informationAnidulafungin Treatment of Candidal Central Nervous System. Infection in a Murine Model
AAC Accepts, published online ahead of print on 8 June 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.00646-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationEfficacy of a Novel Echinocandin, CD101, in a Mouse Model of Azole-Resistant Disseminated Candidiasis
Efficacy of a Novel Echinocandin, CD0, in a Mouse Model of Azole-Resistant Disseminated Candidiasis L. Miesel, K-Y Lin, J. C. Chien, M. L. Hsieh, V. Ong, and K. Bartizal Eurofins Panlabs, Taipei, Taiwan
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationANA ESPINEL-INGROFF* Division of Infectious Diseases, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia
JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 1998, p. 198 202 Vol. 36, No. 1 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology In Vitro Activity of the New Triazole Voriconazole (UK-109,496)
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationAntifungal Activity of Voriconazole on Local Isolates: an In-vitro Study
Original Article Philippine Journal of OPHTHALMOLOGY Antifungal Activity of Voriconazole on Local Isolates: an In-vitro Study Karina Q. De Sagun-Bella, MD, 1 Archimedes Lee D. Agahan, MD, 1 Leo DP. Cubillan,
More informationThe Evolving Role of Antifungal Susceptibility Testing. Gregory A. Eschenauer and Peggy L. Carver
S PECIAL A RTICLE The Evolving Role of Antifungal Susceptibility Testing Gregory A. Eschenauer and Peggy L. Carver Although increasing numbers of hospital microbiology laboratories are performing antifungal
More informationDepartment of Medical Mycology and Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran 3
Curr Med Mycol, 2016 Jun, 2(2): 34-39 Article Original In vitro activity of five antifungal agents against Candida albicans isolates, Sari, Iran Shokohi T 1,2, Badali H 1,2, Amirrajab N 3, Ataollahi MR
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationInterlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: Should the clinical laboratory be testing this agent?
AAC Accepts, published online ahead of print on 9 September 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01519-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5
More informationFKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Clinical Infectious Diseases Advance Access published July 9, 2014 MAJOR ARTICLE FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia Nicholas D. Beyda, 1 Julie John, 1 Abdullah
More informationTriazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2006, p. 529 535 Vol. 44, No. 2 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.2.529 535.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Triazole
More informationThis is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Clinical Medicine Insights: Therapeutics Original Research Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Impact of the New Clinical Breaking Points Proposed
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationyour lab focus susceptibility testing of yeasts and moulds as well as the clinical implications of in vitro antifungal testing.
626 CE update [microbiology and virology] Antifungal Susceptibility Methods and Their Potential Clinical Relevance Ana Espinel-Ingroff, PhD Medical College of Virginia, Virginia Commonwealth University,
More informationIN-VITRO SENSITIVITY OF AMPHOTERICIN B, ITRACONAZOLE AND FLUCONAZOLE - RESISTANT AGAINST CANDIDA ALBICANS
IJPSR (2011), Vol. 2, Issue 11 (Research Article) Received on 03 July, 2011; received in revised form 17 September, 2011; accepted 29 October, 2011 IN-VITRO SENSITIVITY OF AMPHOTERICIN B, ITRACONAZOLE
More informationon March 29, 2019 by guest
JCM Accepts, published online ahead of print on 4 May 2011 J. Clin. Microbiol. doi:10.1128/jcm.00201-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationCD101: A Novel Echinocandin
CD101: A Novel Echinocandin Taylor Sandison, MD MPH Chief Medical Officer TIMM Belgrade, Serbia October 8, 2017 1 Disclosures Dr. Sandison is an employee of and stockholder in Cidara Therapeutics 2 Cidara
More informationCandida albicans 426 (64.0 ) C. albicans non-albicans
74 2006 1) 2) 1) 3) 4) 5) 6) 1) 2) 3) 4) 5) 6) 17 9 26 18 3 8 2003 10 2004 3 6 9,083 666 (7.3 ) Candida albicans 426 (64.0 ) C. albicans non-albicans 233 (35.0 ) Non-albicans Candida glabrata Candida tropicalis
More informationReceived 6 October 2010/Returned for modification 26 December 2010/Accepted 7 January 2011
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2011, p. 1580 1587 Vol. 55, No. 4 0066-4804/11/$12.00 doi:10.1128/aac.01364-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Echinocandin
More informationCaspofungin for the Treatment of Immunocompromised and Severely Ill Children and Neonates with Invasive Fungal Infections
Clinical Medicine Insights: Pediatrics Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Caspofungin for the Treatment of Immunocompromised and Severely
More informationInterpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
CLINICAL MICROBIOLOGY REVIEWS, Apr. 2006, p. 435 447 Vol. 19, No. 2 0893-8512/06/$08.00 0 doi:10.1128/cmr.19.2.435 447.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. Interpretive
More informationUpdate zu EUCAST 2012 Cornelia Lass-Flörl
Update zu EUCAST 2012 Cornelia Lass-Flörl Frühjahrstagung 2012 Paul-Ehrlich-Gesellschaft Sektion Antimykotische Chemotherapie Bonn, 4./5. Mai 2012 Agenda 1. Breakpoints 2. Rationale documents and technical
More informationReceived 27 May 2004/Returned for modification 11 July 2004/Accepted 16 December 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2005, p. 1364 1368 Vol. 49, No. 4 0066-4804/05/$08.00 0 doi:10.1128/aac.49.4.1364 1368.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationPotato Dextrose Agar Antifungal Susceptibility Testing for Yeasts and Molds: Evaluation of Phosphate Effect on Antifungal Activity of CMT-3
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2002, p. 1455 1461 Vol. 46, No. 5 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.5.1455 1461.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationOutcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei
J Antimicrob Chemother 211; 66: 375 3 doi:1.193/jac/dkq446 Advance Access publication 8 December 21 Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata
More informationSusceptibility of Candida Species Isolated From HIV Infected and Newborn Candidaemia Patients to Amphotericin B
OnLine Journal of Biological Sciences 10 (2): 109-113, 2010 ISSN 1608-4217 2010 Science Publications Susceptibility of Candida Species Isolated From HIV Infected and Newborn Candidaemia Patients to Amphotericin
More informationEfficacy of amphotericin B at suboptimal dose combined with. voriconazole in a murine infection by Aspergillus fumigatus with poor in
AAC Accepts, published online ahead of print on 24 June 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00563-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More informationSafety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2006, p. 632 638 Vol. 50, No. 2 0066-4804/06/$08.00 0 doi:10.1128/aac.50.2.632 638.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.
More informationRapid Antifungal Susceptibility Determination for Yeast Isolates by Use of Etest Performed Directly on Blood Samples from Patients with Fungemia
JOURNAL OF CLINICAL MICROBIOLOGY, June 2010, p. 2205 2212 Vol. 48, No. 6 0095-1137/10/$12.00 doi:10.1128/jcm.02321-09 Copyright 2010, American Society for Microbiology. All Rights Reserved. Rapid Antifungal
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationAntifungal Pharmacotherapy
Interpreting Antifungal Susceptibility Testing: Science or Smoke and Mirrors A. W. F O T H E R G I L L, M A, M B A U N I V E R S I T Y O F T E X A S H E A L T H S C I E N C E C E N T E R S A N A N T O
More informationReceived 4 August 2010/Returned for modification 23 October 2010/Accepted 19 November 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2011, p. 561 566 Vol. 55, No. 2 0066-4804/11/$12.00 doi:10.1128/aac.01079-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Candida
More informationon December 11, 2018 by guest
JCM Accepts, published online ahead of print on 12 December 2012 J. Clin. Microbiol. doi:10.1128/jcm.03125-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Biographical Feature;
More informationAntifungal Therapy in Leukemia Patients
Antifungal Therapy in Leukemia Patients UPDATE ECIL 4, 6 September 2011 Raoul Herbrecht, Ursula Flückiger, Bertrand Gachot, Patricia Ribaud, Anne Thiebaut, Catherine Cordonnier UPDATE ECIL 4, 2011 UPDATE
More informationFluconazole Susceptibility Profile of Candida isolates Recovered from Patients Specimens Admitted to Yazd Central Laboratory
Iranian Journal of Pharmaceutical Research (2008), 7 (1): 69-75 Received: June 2007 Accepted: November 2007 Copyright 2008 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and Health
More informationWhat have we learned about systemic antifungals currently available on the market?
2nd ECMM/CEMM Workshop Milano, September 25, 2010 What have we learned about systemic antifungals currently available on the market? Prof. Dr. Georg Maschmeyer Dept. of Hematology, Oncology & Palliative
More informationJapan Antifungal Surveillance Program (1):
183 Japan Antifungal Surveillance Program (1): 2001 2002 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 16 9 14 16 10 12 2001 6 2002 3 2 11 576 fluconazole (FLCZ),
More informationSpecies distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002
Fluconazole J Microbiol Immunol susceptibility Infect of Candida 2004;37:236-241 Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002 Jiun-Ling Wang
More informationglabrata, Candida bracarensis and Candida nivariensis evaluated by time-kill studies
AAC Accepted Manuscript Posted Online March Antimicrob. Agents Chemother. doi:./aac.- Copyright, American Society for Microbiology. All Rights Reserved. In vitro fungicidal activities of anidulafungin,
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationAbout the Editor Gerri S. Hall, Ph.D.
About the Editor Gerri S. Hall, Ph.D. Dr. Hall s professional career has been focused on clinical microbiology: direct clinical activities of various areas such as bacteriology, mycobacteria, STD testing,
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationDepartment of Pathology, University of Iowa College of Medicine, Iowa City, 1 and The JONES Group/JMI Laboratories, North Liberty, 2 Iowa
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2002, p. 1032 1037 Vol. 46, No. 4 0066-4804/02/$04.00 0 DOI: 10.1128/AAC.46.4.1032 1037.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationReceived 5 August 2004/Accepted 26 September 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2005, p. 512 517 Vol. 49, No. 2 0066-4804/05/$08.00 0 doi:10.1128/aac.49.2.512 517.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More information